Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 1/20 | 0.38 |
| ▸ | CMA1 | P23946 | 14/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | CTRC | Q99895 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | ALPG | P10696 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CES2 | O00748 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30765854 | 0.87 | NTRK1 (0.36) | NTRK1POLBTP53KMT2A | |
| SCHEMBL30765764 | 0.82 | CMA1 (0.40) | CMA1CTRCCES2 | |
| SCHEMBL30765846 | 0.79 | CMA1 (0.38) | CMA1POLBCTRCCES2GAA | |
| SCHEMBL30765769 | 0.78 | NTRK1 (0.40) | NTRK1CMA1POLBCTRC | |
| SCHEMBL30765506 | 0.77 | NTRK1 (0.51) | NTRK1CMA1CTRC | |
| SCHEMBL30765582 | 0.76 | KDM4C (0.42) | NTRK1POLBTP53ALDH1A1 | |
| SCHEMBL30765548 | 0.75 | F2 (0.39) | CMA1POLBCTRCKMT2A | |
| SCHEMBL30765916 | 0.75 | CMA1 (0.41) | CMA1POLBCTRC | |
| SCHEMBL30765579 | 0.74 | F3 (0.39) | NTRK1CMA1CTRC | |
| SCHEMBL30765838 | 0.74 | CASP1 (0.41) | CMA1POLBCTRCGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4568666-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Alexion Pharmaceuticals, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| CN-119768164-A | Pharmaceutical compounds for treating complement-mediated disorders | 阿雷克森制药公司 | 2025-04-04 | — | — | CN | disclosed |
| WO-2024035686-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-02-15 | — | — | WO | disclosed |